Genexine (Korea) Top Management
095700 Stock | KRW 5,840 210.00 3.47% |
Genexine employs about 123 people. The company is managed by 8 executives with a total tenure of roughly 287 years, averaging almost 35.0 years of service per executive, having 15.38 employees per reported executive. Analysis of Genexine's management performance can provide insight into the company performance.
You Suh Insider Head Director |
Jungwon Woo Insider Chief Officer |
Genexine |
Genexine Management Team Effectiveness
The company has return on total asset (ROA) of (0.0172) % which means that it has lost $0.0172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.0578) %, meaning that it generated substantial loss on money invested by shareholders. Genexine's management efficiency ratios could be used to measure how well Genexine manages its routine affairs as well as how well it operates its assets and liabilities.Genexine Workforce Comparison
Genexine is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 177. Genexine totals roughly 123 in number of employees claiming about 69% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.41) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.41. Genexine Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Genexine Price Series Summation is a cross summation of Genexine price series and its benchmark/peer.
Genexine Notable Stakeholders
A Genexine stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Genexine often face trade-offs trying to please all of them. Genexine's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Genexine's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
You Suh | Head Director | Profile | |
Jungwon Woo | Chief Officer | Profile | |
Sung CPA | CFO VP | Profile | |
Kyu Kim | Ex Bus | Profile | |
Jae Park | Ex Operation | Profile | |
Young Sung | Chairman Founder | Profile | |
JaiHyun Kwon | Director Transaction | Profile | |
Sung Lee | Head VP | Profile |
About Genexine Management Performance
The success or failure of an entity such as Genexine often depends on how effective the management is. Genexine management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Genexine management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Genexine management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea. Genexine is traded on Korean Securities Dealers Automated Quotations in South Korea.
Please note, the presentation of Genexine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genexine's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genexine's management manipulating its earnings.
Genexine Workforce Analysis
Traditionally, organizations such as Genexine use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Genexine within its industry.Genexine Manpower Efficiency
Return on Genexine Manpower
Revenue Per Employee | 299.4M | |
Revenue Per Executive | 4.6B | |
Net Loss Per Employee | 394.8M | |
Net Loss Per Executive | 6.1B | |
Working Capital Per Employee | 52.9M | |
Working Capital Per Executive | 813.1M |
Complementary Tools for Genexine Stock analysis
When running Genexine's price analysis, check to measure Genexine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genexine is operating at the current time. Most of Genexine's value examination focuses on studying past and present price action to predict the probability of Genexine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genexine's price. Additionally, you may evaluate how the addition of Genexine to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Stocks Directory Find actively traded stocks across global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |